Facilitated By

San Antonio Medical Foundation

Study To Evaluate The Effect Of Dapagliflozin On The Incidence Of Worsening Heart Failure Or Cardiovascular Death In Patients With Chronic Heart Failure With Reduced Ejection Fraction

Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Active

The primary objective of this study is to determine whether dapagliflozin is superior to placebo, when added to standard of care, in reducing the incidence of Cardiovascular (CV) death or a Heart Failure (HF) event (hospitalization for HF or equivalent HF event, ie an urgent HF visit).

Clinical Care
Cardiovascular
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.